Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE)

A phase 3, randomised-controlled, non-inferiority trial

Johan A. Maertens, Issam I. Raad, Kieren Marr, Thomas F. Patterson, Dimitrios P. Kontoyiannis, Oliver A. Cornely, Eric J. Bow, Galia Rahav, Dionysios Neofytos, Mickael Aoun, John W. Baddley, Michael Giladi, Werner J. Heinz, Raoul Herbrecht, William Hope, Meinolf Karthaus, Dong Gun Lee, Olivier Lortholary, Vicki A. Morrison, Ilana Oren & 8 others Dominik Selleslag, Shmuel Shoham, George R. Thompson, Misun Lee, Rochelle M. Maher, Anne Hortense Schmitt-Hoffmann, Bernhardt Zeiher, Andrew J. Ullmann

Research output: Contribution to journalArticle

Abstract

Background Isavuconazole is a novel triazole with broad-spectrum antifungal activity. The SECURE trial assessed efficacy and safety of isavuconazole versus voriconazole in patients with invasive mould disease. Methods This was a phase 3, double-blind, global multicentre, comparative-group study. Patients with suspected invasive mould disease were randomised in a 1:1 ratio using an interactive voice-web response system, stratified by geographical region, allogeneic haemopoietic stem cell transplantation, and active malignant disease at baseline, to receive isavuconazonium sulfate 372 mg (prodrug; equivalent to 200 mg isavuconazole; intravenously three times a day on days 1 and 2, then either intravenously or orally once daily) or voriconazole (6 mg/kg intravenously twice daily on day 1, 4 mg/kg intravenously twice daily on day 2, then intravenously 4 mg/kg twice daily or orally 200 mg twice daily from day 3 onwards). We tested non-inferiority of the primary efficacy endpoint of all-cause mortality from first dose of study drug to day 42 in patients who received at least one dose of the study drug (intention-to-treat [ITT] population) using a 10% non-inferiority margin. Safety was assessed in patients who received the first dose of study drug. This study is registered with ClinicalTrials.gov, number NCT00412893. Findings 527 adult patients were randomly assigned (258 received study medication per group) between March 7, 2007, and March 28, 2013. All-cause mortality from first dose of study drug to day 42 for the ITT population was 19% with isavuconazole (48 patients) and 20% with voriconazole (52 patients), with an adjusted treatment difference of -1·0% (95% CI -7·8 to 5·7). Because the upper bound of the 95% CI (5·7%) did not exceed 10%, non-inferiority was shown. Most patients (247 [96%] receiving isavuconazole and 255 [98%] receiving voriconazole) had treatment-emergent adverse events (p=0·122); the most common were gastrointestinal disorders (174 [68%] vs 180 [69%]) and infections and infestations (152 [59%] vs 158 [61%]). Proportions of patients with treatment-emergent adverse events by system organ class were similar overall. However, isavuconazole-treated patients had a lower frequency of hepatobiliary disorders (23 [9%] vs 42 [16%]; p=0·016), eye disorders (39 [15%] vs 69 [27%]; p=0·002), and skin or subcutaneous tissue disorders (86 [33%] vs 110 [42%]; p=0·037). Drug-related adverse events were reported in 109 (42%) patients receiving isavuconazole and 155 (60%) receiving voriconazole (p

Original languageEnglish (US)
Pages (from-to)760-769
Number of pages10
JournalThe Lancet
Volume387
Issue number10020
DOIs
StatePublished - Feb 20 2016

Fingerprint

Aspergillus
Fungi
Therapeutics
Pharmaceutical Preparations
Non-Randomized Controlled Trials
isavuconazole
Voriconazole
Safety
Triazoles
Mortality
Subcutaneous Tissue
Prodrugs
Stem Cell Transplantation
Drug-Related Side Effects and Adverse Reactions
Population
Skin

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE) : A phase 3, randomised-controlled, non-inferiority trial. / Maertens, Johan A.; Raad, Issam I.; Marr, Kieren; Patterson, Thomas F.; Kontoyiannis, Dimitrios P.; Cornely, Oliver A.; Bow, Eric J.; Rahav, Galia; Neofytos, Dionysios; Aoun, Mickael; Baddley, John W.; Giladi, Michael; Heinz, Werner J.; Herbrecht, Raoul; Hope, William; Karthaus, Meinolf; Lee, Dong Gun; Lortholary, Olivier; Morrison, Vicki A.; Oren, Ilana; Selleslag, Dominik; Shoham, Shmuel; Thompson, George R.; Lee, Misun; Maher, Rochelle M.; Schmitt-Hoffmann, Anne Hortense; Zeiher, Bernhardt; Ullmann, Andrew J.

In: The Lancet, Vol. 387, No. 10020, 20.02.2016, p. 760-769.

Research output: Contribution to journalArticle

Maertens, JA, Raad, II, Marr, K, Patterson, TF, Kontoyiannis, DP, Cornely, OA, Bow, EJ, Rahav, G, Neofytos, D, Aoun, M, Baddley, JW, Giladi, M, Heinz, WJ, Herbrecht, R, Hope, W, Karthaus, M, Lee, DG, Lortholary, O, Morrison, VA, Oren, I, Selleslag, D, Shoham, S, Thompson, GR, Lee, M, Maher, RM, Schmitt-Hoffmann, AH, Zeiher, B & Ullmann, AJ 2016, 'Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): A phase 3, randomised-controlled, non-inferiority trial', The Lancet, vol. 387, no. 10020, pp. 760-769. https://doi.org/10.1016/S0140-6736(15)01159-9
Maertens, Johan A. ; Raad, Issam I. ; Marr, Kieren ; Patterson, Thomas F. ; Kontoyiannis, Dimitrios P. ; Cornely, Oliver A. ; Bow, Eric J. ; Rahav, Galia ; Neofytos, Dionysios ; Aoun, Mickael ; Baddley, John W. ; Giladi, Michael ; Heinz, Werner J. ; Herbrecht, Raoul ; Hope, William ; Karthaus, Meinolf ; Lee, Dong Gun ; Lortholary, Olivier ; Morrison, Vicki A. ; Oren, Ilana ; Selleslag, Dominik ; Shoham, Shmuel ; Thompson, George R. ; Lee, Misun ; Maher, Rochelle M. ; Schmitt-Hoffmann, Anne Hortense ; Zeiher, Bernhardt ; Ullmann, Andrew J. / Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE) : A phase 3, randomised-controlled, non-inferiority trial. In: The Lancet. 2016 ; Vol. 387, No. 10020. pp. 760-769.
@article{8b1675c2563c4a70beeecdf562bcf1d4,
title = "Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): A phase 3, randomised-controlled, non-inferiority trial",
abstract = "Background Isavuconazole is a novel triazole with broad-spectrum antifungal activity. The SECURE trial assessed efficacy and safety of isavuconazole versus voriconazole in patients with invasive mould disease. Methods This was a phase 3, double-blind, global multicentre, comparative-group study. Patients with suspected invasive mould disease were randomised in a 1:1 ratio using an interactive voice-web response system, stratified by geographical region, allogeneic haemopoietic stem cell transplantation, and active malignant disease at baseline, to receive isavuconazonium sulfate 372 mg (prodrug; equivalent to 200 mg isavuconazole; intravenously three times a day on days 1 and 2, then either intravenously or orally once daily) or voriconazole (6 mg/kg intravenously twice daily on day 1, 4 mg/kg intravenously twice daily on day 2, then intravenously 4 mg/kg twice daily or orally 200 mg twice daily from day 3 onwards). We tested non-inferiority of the primary efficacy endpoint of all-cause mortality from first dose of study drug to day 42 in patients who received at least one dose of the study drug (intention-to-treat [ITT] population) using a 10{\%} non-inferiority margin. Safety was assessed in patients who received the first dose of study drug. This study is registered with ClinicalTrials.gov, number NCT00412893. Findings 527 adult patients were randomly assigned (258 received study medication per group) between March 7, 2007, and March 28, 2013. All-cause mortality from first dose of study drug to day 42 for the ITT population was 19{\%} with isavuconazole (48 patients) and 20{\%} with voriconazole (52 patients), with an adjusted treatment difference of -1·0{\%} (95{\%} CI -7·8 to 5·7). Because the upper bound of the 95{\%} CI (5·7{\%}) did not exceed 10{\%}, non-inferiority was shown. Most patients (247 [96{\%}] receiving isavuconazole and 255 [98{\%}] receiving voriconazole) had treatment-emergent adverse events (p=0·122); the most common were gastrointestinal disorders (174 [68{\%}] vs 180 [69{\%}]) and infections and infestations (152 [59{\%}] vs 158 [61{\%}]). Proportions of patients with treatment-emergent adverse events by system organ class were similar overall. However, isavuconazole-treated patients had a lower frequency of hepatobiliary disorders (23 [9{\%}] vs 42 [16{\%}]; p=0·016), eye disorders (39 [15{\%}] vs 69 [27{\%}]; p=0·002), and skin or subcutaneous tissue disorders (86 [33{\%}] vs 110 [42{\%}]; p=0·037). Drug-related adverse events were reported in 109 (42{\%}) patients receiving isavuconazole and 155 (60{\%}) receiving voriconazole (p",
author = "Maertens, {Johan A.} and Raad, {Issam I.} and Kieren Marr and Patterson, {Thomas F.} and Kontoyiannis, {Dimitrios P.} and Cornely, {Oliver A.} and Bow, {Eric J.} and Galia Rahav and Dionysios Neofytos and Mickael Aoun and Baddley, {John W.} and Michael Giladi and Heinz, {Werner J.} and Raoul Herbrecht and William Hope and Meinolf Karthaus and Lee, {Dong Gun} and Olivier Lortholary and Morrison, {Vicki A.} and Ilana Oren and Dominik Selleslag and Shmuel Shoham and Thompson, {George R.} and Misun Lee and Maher, {Rochelle M.} and Schmitt-Hoffmann, {Anne Hortense} and Bernhardt Zeiher and Ullmann, {Andrew J.}",
year = "2016",
month = "2",
day = "20",
doi = "10.1016/S0140-6736(15)01159-9",
language = "English (US)",
volume = "387",
pages = "760--769",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Elsevier Limited",
number = "10020",

}

TY - JOUR

T1 - Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE)

T2 - A phase 3, randomised-controlled, non-inferiority trial

AU - Maertens, Johan A.

AU - Raad, Issam I.

AU - Marr, Kieren

AU - Patterson, Thomas F.

AU - Kontoyiannis, Dimitrios P.

AU - Cornely, Oliver A.

AU - Bow, Eric J.

AU - Rahav, Galia

AU - Neofytos, Dionysios

AU - Aoun, Mickael

AU - Baddley, John W.

AU - Giladi, Michael

AU - Heinz, Werner J.

AU - Herbrecht, Raoul

AU - Hope, William

AU - Karthaus, Meinolf

AU - Lee, Dong Gun

AU - Lortholary, Olivier

AU - Morrison, Vicki A.

AU - Oren, Ilana

AU - Selleslag, Dominik

AU - Shoham, Shmuel

AU - Thompson, George R.

AU - Lee, Misun

AU - Maher, Rochelle M.

AU - Schmitt-Hoffmann, Anne Hortense

AU - Zeiher, Bernhardt

AU - Ullmann, Andrew J.

PY - 2016/2/20

Y1 - 2016/2/20

N2 - Background Isavuconazole is a novel triazole with broad-spectrum antifungal activity. The SECURE trial assessed efficacy and safety of isavuconazole versus voriconazole in patients with invasive mould disease. Methods This was a phase 3, double-blind, global multicentre, comparative-group study. Patients with suspected invasive mould disease were randomised in a 1:1 ratio using an interactive voice-web response system, stratified by geographical region, allogeneic haemopoietic stem cell transplantation, and active malignant disease at baseline, to receive isavuconazonium sulfate 372 mg (prodrug; equivalent to 200 mg isavuconazole; intravenously three times a day on days 1 and 2, then either intravenously or orally once daily) or voriconazole (6 mg/kg intravenously twice daily on day 1, 4 mg/kg intravenously twice daily on day 2, then intravenously 4 mg/kg twice daily or orally 200 mg twice daily from day 3 onwards). We tested non-inferiority of the primary efficacy endpoint of all-cause mortality from first dose of study drug to day 42 in patients who received at least one dose of the study drug (intention-to-treat [ITT] population) using a 10% non-inferiority margin. Safety was assessed in patients who received the first dose of study drug. This study is registered with ClinicalTrials.gov, number NCT00412893. Findings 527 adult patients were randomly assigned (258 received study medication per group) between March 7, 2007, and March 28, 2013. All-cause mortality from first dose of study drug to day 42 for the ITT population was 19% with isavuconazole (48 patients) and 20% with voriconazole (52 patients), with an adjusted treatment difference of -1·0% (95% CI -7·8 to 5·7). Because the upper bound of the 95% CI (5·7%) did not exceed 10%, non-inferiority was shown. Most patients (247 [96%] receiving isavuconazole and 255 [98%] receiving voriconazole) had treatment-emergent adverse events (p=0·122); the most common were gastrointestinal disorders (174 [68%] vs 180 [69%]) and infections and infestations (152 [59%] vs 158 [61%]). Proportions of patients with treatment-emergent adverse events by system organ class were similar overall. However, isavuconazole-treated patients had a lower frequency of hepatobiliary disorders (23 [9%] vs 42 [16%]; p=0·016), eye disorders (39 [15%] vs 69 [27%]; p=0·002), and skin or subcutaneous tissue disorders (86 [33%] vs 110 [42%]; p=0·037). Drug-related adverse events were reported in 109 (42%) patients receiving isavuconazole and 155 (60%) receiving voriconazole (p

AB - Background Isavuconazole is a novel triazole with broad-spectrum antifungal activity. The SECURE trial assessed efficacy and safety of isavuconazole versus voriconazole in patients with invasive mould disease. Methods This was a phase 3, double-blind, global multicentre, comparative-group study. Patients with suspected invasive mould disease were randomised in a 1:1 ratio using an interactive voice-web response system, stratified by geographical region, allogeneic haemopoietic stem cell transplantation, and active malignant disease at baseline, to receive isavuconazonium sulfate 372 mg (prodrug; equivalent to 200 mg isavuconazole; intravenously three times a day on days 1 and 2, then either intravenously or orally once daily) or voriconazole (6 mg/kg intravenously twice daily on day 1, 4 mg/kg intravenously twice daily on day 2, then intravenously 4 mg/kg twice daily or orally 200 mg twice daily from day 3 onwards). We tested non-inferiority of the primary efficacy endpoint of all-cause mortality from first dose of study drug to day 42 in patients who received at least one dose of the study drug (intention-to-treat [ITT] population) using a 10% non-inferiority margin. Safety was assessed in patients who received the first dose of study drug. This study is registered with ClinicalTrials.gov, number NCT00412893. Findings 527 adult patients were randomly assigned (258 received study medication per group) between March 7, 2007, and March 28, 2013. All-cause mortality from first dose of study drug to day 42 for the ITT population was 19% with isavuconazole (48 patients) and 20% with voriconazole (52 patients), with an adjusted treatment difference of -1·0% (95% CI -7·8 to 5·7). Because the upper bound of the 95% CI (5·7%) did not exceed 10%, non-inferiority was shown. Most patients (247 [96%] receiving isavuconazole and 255 [98%] receiving voriconazole) had treatment-emergent adverse events (p=0·122); the most common were gastrointestinal disorders (174 [68%] vs 180 [69%]) and infections and infestations (152 [59%] vs 158 [61%]). Proportions of patients with treatment-emergent adverse events by system organ class were similar overall. However, isavuconazole-treated patients had a lower frequency of hepatobiliary disorders (23 [9%] vs 42 [16%]; p=0·016), eye disorders (39 [15%] vs 69 [27%]; p=0·002), and skin or subcutaneous tissue disorders (86 [33%] vs 110 [42%]; p=0·037). Drug-related adverse events were reported in 109 (42%) patients receiving isavuconazole and 155 (60%) receiving voriconazole (p

UR - http://www.scopus.com/inward/record.url?scp=84959108062&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959108062&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(15)01159-9

DO - 10.1016/S0140-6736(15)01159-9

M3 - Article

VL - 387

SP - 760

EP - 769

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 10020

ER -